As major technology corporations such as Microsoft, Alphabet, Amazon, and Meta prepare to disclose their quarterly financial results, industry experts are closely monitoring two primary aspects: advertising revenue and artificial intelligence-related discussions. For Alphabet and Meta, advertising revenue represents a significant portion of their respective companies’ total income. Analyzing Google’s advertising revenue will provide valuable insights into the overall performance of these businesses. Notably, advertising is crucial for Meta, constituting 98% of the company’s revenue stream. In the case of Microsoft, attention is directed towards artificial intelligence, particularly the role of OpenAI’s ChatGPT. The company may also experience favorable effects from a depreciating US dollar, similar to Apple’s previous quarter.
While all eyes on Wall Street are eagerly eyeing the busy week of earnings, some small cap stocks that demand attention include CLSH, INAB, MGRX, GETY, and IDYA. We would specifically like to draw your attention to this micro cap company CLS Holdings USA, Inc., trading under the symbol (OTCQB: CLSH) (CSE: CLSH).
The company recently announced fiscal third-quarter 2023 financial results that have yet to garner attention from Wall Street. According to the press release, Q3 2023 Financial & Operational Highlights include: net revenue for Q3 2023 was $5.437 million; dispensary revenue increased 6% to $3.529 million, while production revenue decreased 15% to $1.908 million; gross profit for Q3 2023 was $3.019 million, or 56% of net revenue; net loss for Q3 2023 was $1.030 million; and EBITDA for Q3 2023 was $505 thousand.
CLS Holdings USA, Inc. (CLSH) is currently trading at a mere $0.0472 with a 52-week high of $0.50, suggesting a lot of room to the upside. To read more about CLSH, visit https://finance.yahoo.com/news/cls-reports-fiscal-third-quarter-120000776.html
Click on the link below to watch the CEO’s Interview
IN8bio Inc. (INAB) has released new findings from a Phase 1 investigator-sponsored study of INB-100 in leukemia patients. As of April 21, 2023, the data reveal that all evaluable patients (n=7) treated with INB-100 remain alive, progression-free, and in durable complete remission (CR). Significant allogeneic gamma-delta T cell expansion and persistence were observed in patients during the initial 180 days following treatment. Patients administered INB-100 at Dose Level 2 experienced, on average, an 82.9-fold increase in gamma-delta T cell expansion at 60 days compared to patients receiving haploidentical HSCT without INB-100 therapy. Furthermore, gamma-delta T cell levels in Dose Level 2 patients were 12.8 times higher than those in Dose Level 1, indicating a dose-response relationship concerning gamma-delta T cell infusion. Elevated levels of CD4+, CD8+ T cells, NK cells, and B cells were also detected, suggesting a comprehensive positive immune response. Updated safety data from the study indicate low-grade (1-2) graft versus host disease (GvHD) in all treated patients, which was steroid-responsive and exhibited a quicker onset at higher dose levels. No dose-limiting toxicities have been identified thus far. As of the last check on Monday, INAB shares has risen yesterday by 140% to $2.52.
Mangoceuticals, Inc. (MGRX) has risen more than 17% today and is currently trading at $1.71. Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated ED drug branded “Mango,” is pleased to announce its participation in the new Webull Corporate Communication services platform.
Getty Images Holdings, Inc. (GETY) is another stock that has climbed more than 32% and is currently trading at $6.70+1.64. Getty Images Holding Inc. shares soared the most in nine months on Monday after investment firm Trillium Capital LLC proposed to acquire the stock-photo company for $10 a share in cash.
IDEAYA Biosciences Inc. (IDYA) shares experienced an increase in trading on the Nasdaq on Monday after the firm announced preliminary data from a Phase 2 study examining a combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM). The interim results indicated an overall response rate of 45% and a disease control rate of 90% for 20 first-line MUM patients assessed. Additionally, the data revealed an overall response rate of 30% and a disease control rate of 87% for 63 any-line MUM patients evaluated, as reported by IDEAYA. Yesterday, by 12:08 p.m. ET, the company’s stock had climbed 25.9% to $18.79, with over 3.6 million shares traded, surpassing the 65-day average volume of 364,780 shares. The stock had reached a 52-week high of $19.55 earlier in the session. Following discussions with the U.S. Food and Drug Administration, IDEAYA plans to initiate a potentially registration-enabling Phase 2/3 clinical trial for first-line HLA-A2 negative MUM this year. The company noted that the potential patient population for metastatic uveal melanoma is estimated to include around 4,500 patients in the United States and Europe.
Of all the stocks mentioned above, CLSH appears to have tremendous upside potential as the small-cap sector heats up. As always, it’s essential to remain vigilant and conduct thorough due diligence when trading and investing in financial markets.
Disclaimer: InvestorBrandMedia is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available in this article is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall InvestorBrandMedia be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by InvestorBrandMedia., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. InvestorBrandMedia.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Investor Brand Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting InvestorBrandMedia.com/Disclaimer. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. InvestorBrandMedia has been compensated three hundred dollars for advertisement services on CLSH by the company for 04/24/2023 to 05/08/2023.
Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/